NOTCH1 mutations influence survival in chronic lymphocytic leukemia patients

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift


title = "NOTCH1 mutations influence survival in chronic lymphocytic leukemia patients",
abstract = "Background: NOTCH1 PEST domain mutations in chronic lymphocytic leukemia have recently been shown to be of prognostic relevance. Both NOTCH1 and NOTCH2 are constitutively activated in B-cell CLL but not expressed in normal B cells and may be involved in survival and resistance to apoptosis in CLL. We screened for mutations in different parts of both NOTCH1 and NOTCH2 genes and related the changes to survival and other known risk factors. Methods: In a cohort of 209 CLL patients, we used single strand conformation analysis to determine which of the samples carrying the NOTCH mutations and direct dideoxy sequencing was used to determine the exact nucleotide changes. Kaplan-Meier curves and log rank test were used to determine overall survival for NOTCH1 mutated cases and Cox regression analysis was used to calculate hazardous ratios. Results: In the present study, we found NOTCH1 PEST domain mutations in 6.7% of the cases. A shorter overall survival was found in patients with NOTCH1 mutations compared to wildtype (p = 0.049). Further, we also examined the extracellular and the heterodimerisation domains of the NOTCH1 gene and the PEST domain and heterodimerisation domain of the NOTCH2 gene, but no mutations were found in these regions. NOTCH1 mutations were most commonly observed in patients with unmutated IGHV gene (10/14), and associated with a more aggressive disease course. In addition, NOTCH1 mutations were almost mutually exclusive with TP53 mutations. In the combined group of NOTCH1 (6.7%) or TP53 (6.2%) mutations, a significant difference in overall survival compared to the wildtype NOTCH1 and TP53 was found (p = 0.002). Conclusions: Both NOTCH1 and TP53 mutations seem to be independent predictive markers for worse outcome in CLL-patients and this study emphasizes the contention that NOTCH1 mutations is a novel risk marker.",
keywords = "Chronic lymphocytic leukemia, NOTCH1 mutations, TP53 mutations, Prognostic markers",
author = "Kerstin Willander and Dutta, {Ravi Kumar} and Jonas Ungerback and Rebeqa Gunnarsson and Gunnar Juliusson and Mats Fredrikson and Mats Linderholm and Peter Soderkvist",
note = "The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Hematology/Transplantation (013022014)",
year = "2013",
doi = "10.1186/1471-2407-13-274",
language = "English",
volume = "13",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central (BMC)",